Abstract: Disclosed are methods of treating endometriosis in a woman or of preventing endometriosis in a woman at higher than normal risk of developing or suffering recurrence of endometriosis. The inventive methods involve administering to the woman a pharmaceutically acceptable composition containing an aryl hydrocarbon receptor binding ligand, such as indole-3-carbinol, indole-4-carbinol, indole-5-carbinol, diindolylmethane, tryptophan, tryptamine, indole acetic acid, or glucosinolate compounds.

Abstract: Disclosed are methods and compositions for oral contraception and for hormone replacement therapy. Certain compositions of the invention contain androgens, preferably methyltestosterone to be taken in conjunction with estrogens and progestins.

Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.

Abstract: Disclosed are methods and compositions for oral contraception and hormonal therapy. Certain compositions and methods of the invention contain androgens, and preferably methyltestosterone to be combined with estrogen and progestin compositions in a hormonal component of a pharmaceutical composition.

Abstract: Methods of using phytoestrogens, in particular, isoflavones in the prevention and treatment of endometriosis and related disease conditions in females. One method comprises administering a therapeutically effective dosage of a phytoestrogen to females with endometriosis, females having symptoms related to endometriosis, or to females at risk of developing or suffering recurrence of endometriosis. In another method, at least one phytoestrogen may be administered singly or in combination with at least one hormonal therapeutic agent such as GnRH analogs, androgens, progestins, estrogens or any combination thereof. The therapeutically effective dosage of the phytoestrogen or the combination therapeutic ranges between about 25 and about 250 mg/day.

Abstract: Disclosed are methods and compositions for oral contraception. Certain compositions of the invention contain androgens, preferably methyltestosterone to be taken by younger users of the contraceptives to inhibit adverse effects of oral contraceptive use on bone mineral density.

Abstract: Disclosed is a pharmaceutical composition for oral delivery. The composition includes about 1-2 mg mammalian estrogen and about 25-100 mg phytoestrogen. Compositions of the type described above are utilized, for example, in a therapeutic regimen designed to reduce the risk of coronary heart disease and osteoporosis in postmenopausal women. This method comprises the oral administration of a composition comprising a mixture of estrogen and phytoestrogen, the dosages of mammalian estrogen and phytoestrogen being about 1-2 mg, about 25-100 mg, respectively.